Theriva Biologics Q2 2024 cash $16.6M, VIRAGE trial to complete enrollment in Q3

Theriva Biologics, Inc.

2024-Q2 EPS reported -$0.74

Cash $16.6M as of June 30, 2024 vs $23.2M at Dec 31, 2023; runway into Q2 2025.
VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
FDA granted Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.
Goodwill impairment of $4.0M recorded due to stock price decline and increased discount rate.
R&D expenses $3.0M, G&A $1.5M for Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.